Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
Rating
Sector Rating
Recommendation *
Avoid
Neutral
Fair
Quality
Rating Breakdown
Avg.
Relative Strength
The relative strength of a dividend stock indicates whether the stock is uptrending or not. The major determining factor in this rating is whether the stock is trading close to its 52-week-high.
Overall Yield Attractiveness
If a stock’s yield is above or near the market average then it will be rated higher within this parameter. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors.
Dividend Reliability
A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. A company that pays out close to half its earnings as dividends and retains the other half of earnings has ample room to grow its business and pay out more dividends in the future.
Dividend Uptrend
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
Earnings Growth
A stock’s Earnings Growth rating evaluates a company’s expected EPS for the current financial year and compares it to next financial year’s expected EPS. Stocks with single-digit growth estimates will have a higher rating than others, as our research has shown that well-established dividend-paying companies have modest earnings growth estimates.
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
Franklin Genomic Advancements ETF
etf
HELX
Dividend policy
None
Price as of:
$43.78
-0.32
0%
primary theme
Health Care Sector Equity
HELX (ETF)
Franklin Genomic Advancements ETF
Dividend policy
None
Price as of:
$43.78
-0.32
0%
primary theme
Health Care Sector Equity
HELX (ETF)
Franklin Genomic Advancements ETF
Dividend policy
None
Price as of:
$43.78
-0.32
0%
primary theme
Health Care Sector Equity
HELX - Snapshot
Vitals
- YTD Return -1.2%
- 3 Yr Annualized Return N/A
- 5 Yr Annualized Return N/A
- Net Assets $15.1 M
- Holdings in Top 10 43.2%
52 WEEK LOW AND HIGH
$44.10
$24.30
$52.70
Expenses
OPERATING RELATED FEES
- Expense Ratio 12.22%
SALES FEES
- Front Load N/A
- Deferred Load N/A
BROKERAGE FEES
- Turnover 2.20%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) N/A
- IRA N/A
Fund Classification
- Primary Theme Health Care Sector Equity
- Fund Type Exchange Traded Fund
- Investment Style Health
Overview
Next Dividend
Income Profile
Income Risk
Returns Profile
Allocations
Expenses
About
Dividend.com Ratings*
$115.42
+0.91%
$16.24 B
1.27%
$1.45
blocked
blocked
blocked
3.14%
0.10%
$31.47
-2.63%
$10.33 B
0.52%
$0.17
blocked
blocked
blocked
-0.85%
0.70%
$73.97
-3.76%
$8.66 B
0.00%
$0.00
blocked
blocked
blocked
1.57%
0.71%
$21.51
-8.31%
$8.31 B
0.19%
$0.04
blocked
blocked
blocked
-14.58%
0.72%
$130.40
-0.59%
$1.19 B
0.18%
$0.24
blocked
blocked
blocked
5.91%
0.75%
Overview
Next Dividend
Income Profile
Income Risk
Returns Profile
Allocations
Expenses
About
Dividend.com Ratings*
Health Care Select Sector SPDR® Fund
XLV | ETF
$117.95
+1.10%
$24.60 B
1.46%
$1.70
blocked
blocked
blocked
3.98%
0.13%
Vanguard Health Care Index Fund
VHT | ETF
$230.45
+0.72%
$16.24 B
1.27%
$2.90
blocked
blocked
blocked
3.00%
0.10%
iShares Nasdaq Biotechnology ETF
IBB | ETF
$148.73
-0.44%
$9.98 B
0.26%
$0.39
blocked
blocked
blocked
-1.82%
0.46%
iShares U.S. Medical Devices ETF
IHI | ETF
$340.93
+1.17%
$8.24 B
0.24%
$0.81
blocked
blocked
blocked
4.16%
0.42%
SPDR® S&P Biotech ETF
XBI | ETF
$129.63
-2.22%
$7.27 B
0.24%
$0.32
blocked
blocked
blocked
-7.92%
0.35%
HELX - Profile
Distributions
- YTD Total Return -1.2%
- 3 Yr Annualized Total Return N/A
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.37%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameFranklin Genomic Advancements ETF
-
Fund Family NameFranklin Templeton Investments
-
Inception DateFeb 25, 2020
-
Shares Outstanding349969
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerJoyce Lin
Fund Description
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
HELX - Performance
Return Ranking - Trailing
| Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -1.2% | -14.6% | 23.0% | 68.02% |
| 1 Yr | 91.8% | 21.1% | 184.4% | 1.83% |
| 3 Yr | N/A* | 1.3% | 54.0% | N/A |
| 5 Yr | N/A* | 5.2% | 40.3% | N/A |
| 10 Yr | N/A* | 9.4% | 20.2% | N/A |
* Annualized
Return Ranking - Calendar
| Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2020 | N/A | -13.6% | 178.2% | N/A |
| 2019 | N/A | 3.8% | 63.8% | N/A |
| 2018 | N/A | -49.7% | 21.5% | N/A |
| 2017 | N/A | -59.8% | 54.4% | N/A |
| 2016 | N/A | -36.6% | 11.6% | N/A |
Total Return Ranking - Trailing
| Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -1.2% | -14.6% | 23.0% | 68.02% |
| 1 Yr | 91.8% | 14.7% | 184.4% | 1.83% |
| 3 Yr | N/A* | 1.3% | 54.0% | N/A |
| 5 Yr | N/A* | 5.0% | 40.3% | N/A |
| 10 Yr | N/A* | 9.3% | 20.2% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | HELX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2020 | N/A | -13.6% | 178.2% | N/A |
| 2019 | N/A | 3.8% | 63.8% | N/A |
| 2018 | N/A | -25.3% | 22.2% | N/A |
| 2017 | N/A | -10.8% | 54.4% | N/A |
| 2016 | N/A | -36.6% | 11.6% | N/A |
HELX - Holdings
Concentration Analysis
| HELX | Category Low | Category High | HELX % Rank | |
|---|---|---|---|---|
| Net Assets | 15.1 M | 2.48 M | 47.6 B | 90.80% |
| Number of Holdings | 51 | 26 | 452 | 87.93% |
| Net Assets in Top 10 | 6.56 M | 239 K | 19.6 B | 89.08% |
| Weighting of Top 10 | 43.24% | 7.6% | 77.3% | 29.31% |
Top 10 Holdings
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
- WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S 7.15%
Asset Allocation
| Weighting | Return Low | Return High | HELX % Rank | |
|---|---|---|---|---|
| Stocks | 98.79% | 82.92% | 105.23% | 59.20% |
| Cash | 1.21% | -0.19% | 11.60% | 33.33% |
| Preferred Stocks | 0.00% | 0.00% | 5.58% | 89.66% |
| Other | 0.00% | -26.63% | 10.48% | 82.76% |
| Convertible Bonds | 0.00% | 0.00% | 0.02% | 90.23% |
| Bonds | 0.00% | 0.00% | 18.37% | 90.23% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | HELX % Rank | |
|---|---|---|---|---|
| Healthcare | 97.15% | 22.48% | 100.00% | 83.33% |
| Industrials | 1.79% | 0.00% | 4.84% | 1.72% |
| Technology | 1.06% | 0.00% | 27.24% | 7.47% |
| Utilities | 0.00% | 0.00% | 1.24% | 89.66% |
| Real Estate | 0.00% | 0.00% | 6.18% | 90.80% |
| Financial Services | 0.00% | 0.00% | 10.87% | 94.83% |
| Energy | 0.00% | 0.00% | 0.02% | 89.66% |
| Communication Services | 0.00% | 0.00% | 13.83% | 90.23% |
| Consumer Defense | 0.00% | 0.00% | 30.57% | 90.80% |
| Consumer Cyclical | 0.00% | 0.00% | 14.05% | 90.80% |
| Basic Materials | 0.00% | 0.00% | 3.70% | 90.80% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | HELX % Rank | |
|---|---|---|---|---|
| US | 80.86% | 58.67% | 101.51% | 62.07% |
| Non US | 17.93% | 0.00% | 40.32% | 29.89% |
HELX - Expenses
Operational Fees
| HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 12.22% | 0.08% | 25.14% | 2.37% |
| Management Fee | 0.50% | 0.00% | 1.25% | 22.99% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| HELX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 2.20% | 0.70% | 252.00% | 1.22% |
HELX - Distributions
Dividend Yield Analysis
| HELX | Category Low | Category High | HELX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 1.00% | 94.25% |
Dividend Distribution Analysis
| HELX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Quarterly | Annually |
Net Income Ratio Analysis
| HELX | Category Low | Category High | HELX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.37% | -2.53% | 1.74% | 75.88% |
Capital Gain Distribution Analysis
| HELX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
HELX - Fund Manager Analysis
Managers
Joyce Lin
Start Date
Tenure
Tenure Rank
Feb 25, 2020
1.1
1.1%
Ms. Lin has been a portfolio manager of Franklin Tenmpleton, providing research and advice on the purchases and sales of individual securities, and portfolio risk assessment. She joined Franklin Templeton in 2014. Prior to joining Franklin Templeton in 2014, Ms. Lin was a research associate at Cooke & Bieler, a value based investment management firm.
Matthew Moberg
Start Date
Tenure
Tenure Rank
Feb 25, 2020
1.1
1.1%
Moberg is a Vice President, Portfolio Manager and Research Analyst of Franklin Advisers, Inc. He provides research and advice on the purchases and sales of individual securities, and portfolio risk assessment. He joined Franklin Templeton Investments in 1998. Moberg holds the Certified Public Accountant designation. Mr. Moberg earned his B.A. in history from Washington and Lee University and an M.B.A. with distinction from the University of Michigan.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.04 | 23.56 | 7.32 | 20.93 |
